Be very interested to hear people's thoughts re impact on ADO...

Be very interested to hear people's thoughts re impact on ADO relationship with BBI

BBI Solutions Licenses 3DNA® Signal Amplification Technology from Genisphere for Lateral Flow Rapid Test Applications 10th November 2014 10th November 2014 – CARDIFF, U.K. – BBI Solutions (BBI), part of the BBI Group, a trusted partner to some of the world’s leading diagnostic and healthcare organisations for over 25 years, today announced it has signed an agreement to license 3DNA® Signal Amplification technology from Genisphere, LLC for development of lateral flow rapid test applications. BBI will utilise the technology to develop lateral flow assays with enhanced performance and sensitivity, particularly for assay development and manufacturing services for the point-of-care diagnostic market. The parties also agreed to negotiate further licenses to permit BBI to commercialise such products. The financial terms of the partnership were not disclosed. “A key goal for rapid test manufacturers is to push the level of detection to the absolute maximum”, said Leigh Thomas, Chief Commercial Officer at BBI Solutions. “We believe that Genisphere’s 3DNA Signal Amplification technology will provide BBI with an additional valuable tool to drive assay performance, expand the life cycle of lateral flow assays, and offer lateral flow solutions to enable the level of handheld POC analysis that may not have been previously possible.” Genisphere’s 3DNA technology has been used to improve the limit of detection in a variety of assay platforms, including microarray, ELISA, bead-based flow cytometry and lateral flow. The technology can provide a significant improvement in sensitivity where conventional optimisation methods have not delivered the required performance. The formal partnership between the companies has resulted from a three-year R&D collaboration focused on customising the 3DNA technology to BBI’s rapid test platforms and those of its customers. “Genisphere is delighted to have this relationship with BBI, a market leader in lateral flow rapid test development and manufacturing,” said Jim Kadushin, Genisphere’s chief operations officer. “Our combined efforts will result in BBI providing its partners with an edge in this competitive landscape, and the true winner will be the patient.” BBI will be showcasing the benefits of the 3DNA Signal Amplification technology in lateral flow applications at the Medica exhibition in Dusseldorf from 12th to 15th November 2014. Click here for more information on 3DNA®. News Categories